Compare Stocks: KLRS, SVA, UPB, and IPSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$2.01 -1.2%	$2.16	$0.44 ▼ $3.04	$363.06M	1.57	1.36 million shs	71,511 shs
KLRS Kalaris Therapeutics	$4.00 -0.7%	$4.17	$3.03 ▼ $11.88	$95.24M	0.2	144,120 shs	6,331 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.79	N/A	N/A
UPB Upstream Bio	$6.53 -2.5%	$6.95	$5.85 ▼ $33.68	$357.16M	1.26	851,948 shs	17,907 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	0.00%	-1.93%	+0.50%	-13.98%	+314.29%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
UPB Upstream Bio	0.00%	-4.02%	+6.02%	-17.20%	-60.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$2.01 -1.2%	$2.16	$0.44 ▼ $3.04	$363.06M	1.57	1.36 million shs	71,511 shs
KLRS Kalaris Therapeutics	$4.00 -0.7%	$4.17	$3.03 ▼ $11.88	$95.24M	0.2	144,120 shs	6,331 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.79	N/A	N/A
UPB Upstream Bio	$6.53 -2.5%	$6.95	$5.85 ▼ $33.68	$357.16M	1.26	851,948 shs	17,907 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	0.00%	-1.93%	+0.50%	-13.98%	+314.29%
KLRS Kalaris Therapeutics	0.00%	-2.89%	+14.81%	-17.76%	-1.23%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
UPB Upstream Bio	0.00%	-4.02%	+6.02%	-17.20%	-60.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSC Century Therapeutics	2.43	Hold	$4.75	136.91% Upside
KLRS Kalaris Therapeutics	2.88	Moderate Buy	$18.75	368.75% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
UPB Upstream Bio	2.43	Hold	$29.67	354.66% Upside

Current Analyst Ratings Breakdown

Latest KLRS, SVA, UPB, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/3/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/28/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	IPSC Century Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	KLRS Kalaris Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
6/12/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$35.00 ➝ $8.00
6/9/2026	KLRS Kalaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSC Century Therapeutics	N/A	N/A	$0.01 per share	152.26	$1.82 per share	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$4.21 per share	N/A
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
UPB Upstream Bio	$3.16M	113.17	N/A	N/A	$6.29 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSC Century Therapeutics	-$9.58M	-$0.93	N/A	N/A	N/A	N/A	-49.51%	-38.09%	11/12/2026 (Estimated)
KLRS Kalaris Therapeutics	-$43.44M	-$2.02	N/A	N/A	N/A	N/A	-71.71%	-42.95%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest KLRS, SVA, UPB, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	-$0.17	-$0.06	-$0.17	$2.17 million	N/A
8/11/2026	Q2 2026	KLRS Kalaris Therapeutics	-$0.50	-$0.48	+$0.02	-$0.48	N/A	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSC Century Therapeutics	N/A	8.28	8.28
KLRS Kalaris Therapeutics	N/A	10.98	10.98
SVA Sinovac Biotech	0.04	6.07	5.97
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSC Century Therapeutics	50.20%
KLRS Kalaris Therapeutics	66.05%
SVA Sinovac Biotech	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
IPSC Century Therapeutics	2.40%
KLRS Kalaris Therapeutics	68.10%
SVA Sinovac Biotech	12.79%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSC Century Therapeutics	170	181.08 million	176.73 million	Optionable
KLRS Kalaris Therapeutics	110	23.81 million	7.59 million	N/A
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
UPB Upstream Bio	38	54.77 million	45.76 million	N/A

KLRS, SVA, UPB, and IPSC Headlines

Recent News About These Companies

Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Target Price at $29.67

August 30 at 2:44 AM | americanbankingnews.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29 at 4:10 AM | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

August 14, 2026 | marketbeat.com

Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright

August 14, 2026 | marketbeat.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

August 11, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

August 6, 2026 | marketbeat.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

June 19, 2026 | businesswire.com

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...

June 14, 2026 | markets.businessinsider.com

Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms

June 14, 2026 | quiverquant.comQ

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

June 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, SVA, UPB, and IPSC Company Descriptions

Century Therapeutics NASDAQ:IPSC

$2.00 -0.03 (-1.23%)

As of 10:13 AM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Kalaris Therapeutics NASDAQ:KLRS

$4.00 -0.03 (-0.74%)

As of 10:13 AM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/28/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Upstream Bio NASDAQ:UPB

$6.52 -0.17 (-2.47%)

As of 10:14 AM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KLRS, SVA, UPB, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KLRS, SVA, UPB, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KLRS, SVA, UPB, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, SVA, UPB, and IPSC Company Descriptions

Century Therapeutics NASDAQ:IPSC

Kalaris Therapeutics NASDAQ:KLRS

Sinovac Biotech NASDAQ:SVA

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KLRS, SVA, UPB, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KLRS, SVA, UPB, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KLRS, SVA, UPB, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, SVA, UPB, and IPSC Company Descriptions

Century Therapeutics NASDAQ:IPSC

Kalaris Therapeutics NASDAQ:KLRS

Sinovac Biotech NASDAQ:SVA

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools